Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype
DrugBaron
JANUARY 31, 2024
Take RxNfinity, the first “dynamic chemical space” that leverages AI strategies to design small molecule ligands for “undruggable targets” or with complex pharmacologies: it has delivered hit rates above 50% with sub-micromolar novel compounds on multiple client projects, far exceeding the capabilities of competitor discovery technologies.
165 
Let's personalize your content